var data={"title":"Piperacillin and tazobactam sodium: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Piperacillin and tazobactam sodium: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6784?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">see &quot;Piperacillin and tazobactam sodium: Drug information&quot;</a> and <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Piperacillin and tazobactam sodium: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210401\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zosyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210402\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>AJ-PIP/TAZ;</li>\n      <li>Piperacillin and Tazobactam for Injection;</li>\n      <li>Tazocin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049416\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Beta-lactam and Beta-lactamase Inhibitor Combination</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Penicillin (Antipseudomonal)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675525\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Zosyn (piperacillin and tazobactam) is a combination product; each 3.375 <b>g</b> vial contains 3 <b>g</b> piperacillin sodium and 0.375 <b>g</b> tazobactam sodium in an 8:1 ratio. Dosage recommendations are based on the <b>piperacillin</b> component.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Red Book</i> (AAP 2015): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA &le;14 days: 100 mg piperacillin/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA 15 to 28 days: 100 mg piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Body weight &ge;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA &le;7 days: 100 mg piperacillin/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA 8 to 28 days: 100 mg piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bradley 2016: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Body weight &le;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA &le;7 days: 100 mg piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">PNA 8 to 28 days: 80 mg piperacillin/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Body weight &gt;2 kg: PNA &le;60 days: 80 mg piperacillin/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PMA-directed dosing (Cohen-Wolkowiez 2014): <b>Note:</b> Dosing based on a pharmacokinetic study of 32 patients (GA: Median: 30 weeks; range: 23 to 40 weeks; PNA: Median: 8 days; range: 1 to 60 days). Limited data available: IV:</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">PMA &le;30 weeks: 100 mg piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">PMA &gt;30 to 35 weeks: 80 mg piperacillin/kg/dose every 6 hours</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">PMA &gt;35 to 49 weeks: 80 mg piperacillin/kg/dose every 4 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049409\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">see &quot;Piperacillin and tazobactam sodium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Zosyn (piperacillin and tazobactam) is a combination product; each 3.375 <b>g</b> vial contains 3 <b>g</b> piperacillin sodium and 0.375 <b>g</b> tazobactam sodium in an 8:1 ratio. Dosage recommendations are based on the <b>piperacillin</b> component. <b>Note:</b> Some centers divide doses every 6 hours for enhanced pharmacodynamic profile. Unless otherwise specified, dosing presented is based on traditional infusion method (IV infusion over 30 minutes). Dosing is presented in mg/kg/dose and mg/kg/<b>day</b>; use precaution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Severe infection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;2 months: IV: 80 mg piperacillin/kg/dose every 6 hours (Bradley 2016); some experts have recommended 80 mg piperacillin/kg/dose every 4 hours based on a pharmacokinetic study (Cohen-Wolkowiez 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 2 to 9 months: IV: 80 mg piperacillin/kg/dose every 8 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;9 months, Children, and Adolescents: IV: 100 mg piperacillin/kg/dose every 8 hours; maximum daily dose: 16 <b>g</b> piperacillin/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Appendicitis and/or peritonitis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 2 to 9 months: 80 mg of piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;9 months and Children weighing &le;40 kg: 100 mg piperacillin/kg/dose every 8 hours; maximum dose: 3,000 mg piperacillin/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children weighing &gt;40 kg and Adolescents: 3,000 mg piperacillin every 6 hours; maximum daily dose: 16 <b>g</b> piperacillin/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pseudomonal lung infection:</b> Infants, Children, and Adolescents: <b>Note:</b> Multiple dosing approaches have been evaluated; optimal dose may vary based on disease severity, susceptibility patterns (eg, MIC), or patient tolerability:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Standard dosing range: IV: 240 to 400 mg piperacillin/kg/<b>day</b> divided every 8 hours (Kliegman 2011); others have used 350 to 400 mg/kg/<b>day</b> divided every 4 hours in early piperacillin trials (Zobell 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose: Limited data available: IV: 450 mg piperacillin/kg/<b>day</b> divided every 4 to 6 hours or 600 mg piperacillin/kg/<b>day</b> divided every 4 hours has been described from early studies of piperacillin alone; usual maximum daily dose: 18 to 24 <b>g</b> piperacillin/<b>day</b>. <b>Note:</b> Piperacillin doses &gt;600 mg/kg/<b>day</b> or an extended duration of therapy (&gt;14 days) have been associated with dose-related adverse effects including serum sickness, immune-mediated hemolytic anemia and bone marrow suppression (Zobell 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment: </b>Children and Adolescents: IV: 240 mg piperacillin/kg/<b>day</b> divided every 8 hours in combination with an aminoglycoside for at least 6 weeks; maximum daily dose: 18 <b>g</b> piperacillin/<b>day</b> (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 200 to 300 mg piperacillin/kg/<b>day</b> divided every 6 to 8 hours; maximum daily dose: 12 <b>g</b> piperacillin/<b>day</b> (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections:</b> Infants, Children, and Adolescents: IV: 60 to 75 mg piperacillin/kg/dose every 6 hours (in combination with vancomycin for empiric therapy); continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical antimicrobial prophylaxis</b> (Bratzler 2013): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 2 to 9 months: 80 mg piperacillin/kg 30 to 60 minutes prior to procedure; may repeat in 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;9 months, Children, and Adolescents weighing &le;40 kg: 100 mg piperacillin/kg 30 to 60 minutes prior to procedure; may repeat in 2 hours. Maximum dose: 3,000 mg piperacillin/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents weighing &gt;40 kg: 3,000 mg piperacillin 30 to 60 minutes prior to procedure; may repeat in 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extended-infusion method:</b> Limited data available: Children and Adolescents: IV: 100 mg piperacillin/kg/dose infused over 4 hours 3 times daily. Dosing based on a prospective, observational study (n=332) in a single children's hospital comparing the extended interval method to traditional dosing (Nichols 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dosing expressed as total dose of combination product (piperacillin/tazobactam); dosing presented is based on traditional infusion method (IV infusion over 30 minutes) unless otherwise specified as the extended infusion method (IV infusion over 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> IV: 3.375 <b>g</b> (3,000 mg piperacillin/375 mg tazobactam) every 6 hours or 4.5 <b>g</b> (4,000 mg piperacillin/500 mg tazobactam) every 6 to 8 hours; maximum: 16 <b>g</b> piperacillin/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bite wounds (animal):</b> IV: 3.375 <b>g</b> every 6 to 8 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diverticulitis, intra-abdominal abscess, peritonitis:</b> IV: 3.375 <b>g</b> every 6 hours; <b>Note:</b> Some clinicians use 4.5 <b>g</b> every 8 hours for empiric coverage since the %time&gt;MIC is similar between the regimens for most pathogens; however, this regimen is <b>not</b> recommended for nosocomial pneumonia or <i>Pseudomonas</i> coverage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, nosocomial:</b> IV: 4.5 <b>g</b> every 6 hours for 7 to 14 days (when used empirically, combination with an aminoglycoside or antipseudomonal fluoroquinolone is recommended; consider discontinuation of additional agent if <i>P. aeruginosa</i> is not isolated)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infection:</b> IV: 3.375 <b>g</b> every 6 hours for 7 to 10 days. <b>Note:</b> For severe diabetic foot infections, recommended treatment duration is up to 4 weeks depending on severity of infection and response to therapy (Lipsky 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Necrotizing infections:</i> IV: 3.375 <b>g</b> every 6 to 8 hours (in combination with vancomycin for empiric therapy); continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical site infections (intestinal or genitourinary tract):</b> IV: 3.375 <b>g</b> every 6 hours <b>or </b>4.5 <b>g</b> every 8 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following have been used by some clinicians (Aronoff 2007): <b>Note:</b> Dosage recommendations are based on the piperacillin component. Dosing based on a usual dose of 200 to 300 mg piperacillin kg/<b>day</b> in divided doses every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg piperacillin/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD): Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose: 50 to 75 mg piperacillin/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): Peritoneal dialysis removes 21% of tazobactam and 6% of piperacillin: 50 to 75 mg piperacillin/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 35 to 50 mg piperacillin kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: <b>Note:</b> Dosing expressed as total dose of combination product (piperacillin/tazobactam).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Traditional infusion method (ie, IV infusion over 30 minutes): Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nosocomial pneumonia:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;40 mL/minute: No adjustment needed</p>\n    <p style=\"text-indent:-4em;margin-left:12em;\">CrCl 20 to 40 mL/minute: 3.375 <b>g</b> every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;20 mL/minute: 2.25 <b>g</b> every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: 2.25 <b>g</b> every 8 hours with an additional dose of 0.75 <b>g</b> after each dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CAPD: Adults: 2.25 <b>g</b> every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">All other indications:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;40 mL/minute: No adjustment needed</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 20 to 40 mL/minute: 2.25 <b>g</b> every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;20 mL/minute: 2.25 <b>g</b> every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose: 2.25 <b>g</b> every 12 hours with an additional dose of 0.75 <b>g</b> after each dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CAPD: Peritoneal dialysis removes 21% of tazobactam and 6% of piperacillin: 2.25 <b>g</b> every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosing adjustment required</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210378\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note</b>: 8:1 ratio of piperacillin sodium/tazobactam sodium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infusion [premixed iso-osmotic solution]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g (50 mL) [contains edetate disodium, sodium 128 mg (5.58 mEq)] </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 3.375 g: Piperacillin 3 g and tazobactam 0.375 g (50 mL)  [contains edetate disodium, sodium 192 mg (8.38 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 4.5 g: Piperacillin 4 g and tazobactam 0.5 g (100 mL) [contains edetate disodium, sodium 256 mg (11.17 mEq)] </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g; 3.375 g: Piperacillin 3 g and tazobactam 0.375 g; 4.5 g: Piperacillin 4 g and tazobactam 0.5 g; 40.5 g: Piperacillin 36 g and tazobactam 4.5 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 2.25 g: Piperacillin 2 g and tazobactam 0.25 g [contains edetate disodium, sodium 130 mg (5.68 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 3.375 g: Piperacillin 3 g and tazobactam 0.375 g [contains edetate disodium, sodium 195 mg (8.52 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 4.5 g: Piperacillin 4 g and tazobactam 0.5 g [contains edetate disodium, sodium 260 mg (11.36 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zosyn: 40.5 g: Piperacillin 36 g and tazobactam 4.5 g [contains edetate disodium, sodium 2304 mg (100.4 mEq); bulk pharmacy vial]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210362\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Excludes infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049419\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion: Administer over 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended IV infusion: Administration over 3 to 4 hours has been reported in pediatric and adult patients (Kim 2007; Nichols 2012; Shea 2009).</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides <i>in vitro</i>. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy <i>in vivo</i>, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered. <b>Note:</b> Reformulated Zosyn containing EDTA has been shown to be compatible <i>in vitro</i> for Y-site infusion with amikacin and gentamicin diluted in NS or D<sub>5</sub>W (applies <b>only</b> to specific concentrations and varies by product; consult manufacturer&rsquo;s labeling). Reformulated Zosyn containing EDTA is <b>not</b> compatible with tobramycin. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210395\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vials: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Use single-dose or bulk vials immediately after reconstitution. Discard any unused portion after 24 hours if stored at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) or after 48 hours if stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze vials after reconstitution. Stability in D5W or NS has been demonstrated for up to 24 hours at room temperature and up to 1 week at refrigerated temperature. Stability in an ambulatory IV infusion pump has been demonstrated for a period of 12 hours at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Galaxy containers: Store at or below -20&deg;C (-4&deg;F). The thawed solution is stable for 14 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or 24 hours at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not refreeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049418\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of moderate to severe infections caused by susceptible organisms (FDA approved in ages &ge;2 months and adults); including sepsis, postpartum endometritis or pelvic inflammatory disease, intra-abdominal infections, uncomplicated or complicated infections involving skin and skin structures, moderate severity community-acquired pneumonia, and moderate to severe nosocomial pneumonia. Tazobactam expands activity of piperacillin to include beta-lactamase producing strains of <i>S. aureus</i>, <i>H. influenzae</i>, <i>B. fragilis</i>, <i>Klebsiella</i>, <i>E. coli</i>, and <i>Acinetobacter</i>. When piperacillin and tazobactam is used to treat nosocomial pneumonia caused by <i>P. aeruginosa</i>, combination therapy with an aminoglycoside is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210432\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zosyn may be confused with Zofran, Zyvox</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tazact [India] may be confused with Tazac brand name for nizatidine [Australia]; Tiazac brand name for dilTIAZem [US, Canada]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210428\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also see piperacillin monograph.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, hypotension, phlebitis, thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, insomnia, rigors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, purpura, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased serum albumin, decreased serum glucose, decreased serum total protein, electrolyte disturbance (increases and decreases in sodium, potassium, and calcium), hyperglycemia, hypoglycemia, hypokalemia, increased gamma-glutamyl transferase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea, pseudomembranous colitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, eosinophilia, leukopenia, neutropenia, positive direct Coombs test, prolonged bleeding time, prolonged partial thromboplastin time, prolonged prothrombin time, thrombocythemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure (in critically ill patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute generalized exanthemous pustulosis, agranulocytosis, anaphylactoid reaction, <i>Clostridium difficile-</i>associated diarrhea, convulsions, DRESS syndrome, eosinophilic pneumonitis, erythema multiforme, exfoliative dermatitis, hemolytic anemia, hepatitis, hypersensitivity reaction, interstitial nephritis, jaundice, pancytopenia, shock, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210385\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to penicillins, cephalosporins, beta-lactamase inhibitors, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210366\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic/anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or history of sensitivity to multiple allergens. Discontinue treatment and institute appropriate therapy if an allergic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: Serious skin reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), acute exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. If a skin rash develops, monitor closely. Discontinue if lesions progress.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte abnormalities: Sodium content (2.84 mEq per gram of piperacillin) should be considered in patients requiring sodium restriction. Assess electrolytes periodically in patients with low potassium reserves, especially those receiving cytotoxic therapy or diuretics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Prothrombin time, platelet aggregation, and clotting time abnormalities have been reported with piperacillin and particularly in patients with renal impairment. Discontinue if thrombocytopenia or bleeding occurs. Leukopenia/neutropenia may occur; appears to be reversible and most frequently associated with prolonged administration. Assess hematologic parameters periodically, especially with prolonged (&ge;21 days) use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cystic fibrosis: An increased frequency of fever and rash has been reported in patients with cystic fibrosis receiving piperacillin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment or in hemodialysis patients. Dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Critically ill patients: Use of piperacillin and tazobactam in critically ill patients may delay renal recovery as compared to other beta-lactam antibacterial drugs; consider alternative treatment options in critically ill patients. If alternative treatment options are inadequate or unavailable, closely monitor renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299884\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210371\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12708&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucloxacillin: Piperacillin may increase the serum concentration of Flucloxacillin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Piperacillin may enhance the nephrotoxic effect of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vecuronium: Piperacillin may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210387\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Piperacillin and tazobactam both cross the placenta and are found in the fetal serum, placenta, amniotic fluid, and fetal urine. When used during pregnancy, the clearance and volume of distribution of piperacillin/tazobactam are increased; half-life and AUC are decreased (Bourget 1998). Piperacillin/tazobactam is approved for the treatment of postpartum gynecologic infections, including endometritis or pelvic inflammatory disease, caused by susceptible organisms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049415\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, bleeding time especially in patients with renal impairment; periodic tests of renal, hepatic, and hematologic function; observe for changes in bowel frequency, CBC with differential; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210365\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Piperacillin inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Piperacillin exhibits time-dependent killing. Tazobactam inhibits many beta-lactamases, including staphylococcal penicillinase and Richmond-Sykes types 2, 3, 4, and 5, including extended spectrum enzymes; it has only limited activity against class 1 beta-lactamases other than class 1C types.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210384\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note: </b>Both AUC and peak concentrations are dose proportional </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Well into lungs, intestinal mucosa, uterus, ovary, fallopian tube, interstitial fluid, gallbladder, and bile; penetration into CSF is low in subjects with noninflamed meninges; V<sub>d</sub>: Children and Adults: 0.243 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Piperacillin: ~26% to 33%; Tazobactam: 31% to 32% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Piperacillin: 6% to 9% to desethyl metabolite (weak activity) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazobactam: ~22% to inactive metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: IM: Piperacillin: 71%; Tazobactam: 84%  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (pediatric data: Reed 1994): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Piperacillin: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 2 to 5 months: 1.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 6 to 23 months: 0.9 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 2 to 12 years: 0.7 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 0.7 to 1.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metabolite: 1 to 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazobactam: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 2 to 5 months: 1.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 6 to 23 months: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 2 to 12 years: 0.8 to 0.9 hour </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 0.7 to 0.9 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Immediately following completion of 30-minute infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Clearance of both piperacillin and tazobactam are directly proportional to renal function; Infants and Children 9 months to 12 years: 5.64 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Piperacillin: Urine (68% as unchanged drug); feces (10% to 20%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tazobactam: Urine (80% as unchanged drug; remainder as inactive metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6856652\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zosyn Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2-0.25 gm/50 mL (50 mL): $18.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3-0.375 gm/50 mL (50 mL): $27.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4-0.5 g/100 mL (100 mL): $34.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Piperacillin Sod-Tazobactam So Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.25 (2-0.25) g (1): $8.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.375 (3-0.375) g (1): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5 (4-0.5) g (1): $17.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13.5 (12-1.5) g (1): $58.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40.5 (36-4.5) g (1): $176.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zosyn Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.25 (2-0.25) g (1): $8.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.375 (3-0.375) g (1): $12.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5 (4-0.5) g (1): $16.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40.5 (36-4.5) g (1): $151.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210390\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Albactam (TH);</li>\n      <li>Ampito (LK);</li>\n      <li>Astaz-P (TH);</li>\n      <li>Aurotaz (QA);</li>\n      <li>Betamycin (TW);</li>\n      <li>Co-Tazo (TW);</li>\n      <li>Jeita (TW);</li>\n      <li>Pipercin (IE);</li>\n      <li>Pipertaz (TH);</li>\n      <li>Piptabac (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Piptaz (PH, VN);</li>\n      <li>Pisa (LK);</li>\n      <li>Plepra-T 4.5 (PH);</li>\n      <li>Pletzolyn (PH);</li>\n      <li>Prizma (QA);</li>\n      <li>Pybactam (ID);</li>\n      <li>Sixacin (PY);</li>\n      <li>Tabaxin (KR);</li>\n      <li>Tapicin (MY);</li>\n      <li>Tasovak (MX);</li>\n      <li>Tazar (UA);</li>\n      <li>Tazepen (MT);</li>\n      <li>Tazin (LK);</li>\n      <li>Tazobac (CH, DE, LI);</li>\n      <li>Tazobact (HR);</li>\n      <li>Tazobak (LK, PH);</li>\n      <li>Tazocillin (BD, IL);</li>\n      <li>Tazocilline (FR);</li>\n      <li>Tazocin (AE, BE, BG, BH, BR, CN, CO, CR, CY, CZ, DK, EC, EE, EG, GB, GT, HK, HN, HR, ID, IE, IL, IQ, IR, IT, JO, KR, KW, LB, LI, LT, LU, LY, MT, MX, NI, NL, OM, PA, PE, PH, PK, PL, QA, RO, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, VN, YE);</li>\n      <li>Tazocin EF (AU, DO, MY, NZ);</li>\n      <li>Tazomax (UY);</li>\n      <li>Tazonam (AR, AT, CL, PY);</li>\n      <li>Tazopen (BD, PH);</li>\n      <li>Tazoperan (KR);</li>\n      <li>Tazopip (AU, IL);</li>\n      <li>Tazopril (VE);</li>\n      <li>Tazorex (IL, MT);</li>\n      <li>Tazosyn (BD);</li>\n      <li>Tazpen (MY, SG, UA);</li>\n      <li>Tebranic (TH);</li>\n      <li>Victalis (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vigocid (PH);</li>\n      <li>Zobaction (LK);</li>\n      <li>Zopercin (VN);</li>\n      <li>Zopertsyn (UA);</li>\n      <li>Zosyn (BB, IN, JP, LI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Sertin A, Lesne-Hulin A, et al, &quot;Influence of Pregnancy on the Pharmacokinetic Behaviour and the Transplacental Transfer of the Piperacillin-Tazobactam Combination,&quot; <i>Eur J Obstet Gynecol Reprod Biol</i>, 1998, 76(1):21-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/9481541/pubmed\" target=\"_blank\" id=\"9481541\">9481541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bryson HM and Brogden RN, &ldquo;Piperacillin/Tazobactam. A Review of its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Potential,&rdquo; <i>Drugs</i>, 1994, 47(3):506-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/7514977/pubmed\" target=\"_blank\" id=\"7514977\">7514977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen-Wolkowiez M, Watt KM, Zhou C, et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. <i>Antimicrob Agents Chemother</i>. 2014;58(5):2856-2865.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/24614369 /pubmed\" target=\"_blank\" id=\"24614369 \">24614369 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flidel-Rimon O, Friedman S, Gradstein S, et al, &quot;Reduction in Multiresistant Nosocomial Infections in Neonates Following Substitution of Ceftazidime With Piperacillin/Tazobactam in Empiric Antibiotic Therapy,&quot; <i>Acta Paediatr</i>, 2003, 92(10):1205-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/14632339/pubmed\" target=\"_blank\" id=\"14632339\">14632339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flidel-Rimon O, Friedman S, Leibovitz E, et al, &quot;The Use of Piperacillin/Tazobactam (in Association With Amikacin) in Neonatal Sepsis: Efficacy and Safety Data,&quot;<i> Scand J Infect Dis</i>, 2006, 38(1):36-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/16338836/pubmed\" target=\"_blank\" id=\"16338836\">16338836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim A, Sutherland CA, Kuti JL, et al, &quot;Optimal Dosing of piperacillin-Tazobactam for the Treatment of <i>Pseudomonas aeruginosa</i> Infections: Prolonged or Continuous Infusion?&quot; <i>Pharmacotherapy</i>, 2007, 27(11):1490-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/17963458/pubmed\" target=\"_blank\" id=\"17963458\">17963458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier;2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nichols KR, Knoderer CA, Cox EG, et al, &quot;System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective,&quot; <i>Clin Ther</i>, 2012, 34(6):1459-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/22657253/pubmed\" target=\"_blank\" id=\"22657253\">22657253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pillay T, Pillay DG, Adhikari M, et al, &quot;Piperacillin/Tazobactam in the Treatment of <i>Klebsiella pneumoniae</i> Infections in Neonates,&quot; <i>Am J Perinatol</i>, 1998, 15(1):47-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/9475688/pubmed\" target=\"_blank\" id=\"9475688\">9475688</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, Goldfarb J, Yamashita T, et al, &ldquo;Single-Dose Pharmacokinetics of Piperacillin and Tazobactam in Infants and Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1994, 38(12):2817-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/ 7695268 /pubmed\" target=\"_blank\" id=\" 7695268 \"> 7695268 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubino CM, Gal P, and Ransom JL, &quot;A Review of the Pharmacokinetic and Pharmacodynamic Characteristics of Beta-Lactam/Beta-Lactamase Inhibitor Combination Antibiotics in Premature Infants,&quot; <i>Pediatr Infect Dis J</i>, 1998, 17(12):1200-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/9877383/pubmed\" target=\"_blank\" id=\"9877383\">9877383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shea KM, Cheatham SC, Smith DW, et al, &quot;Comparative Pharmacodynamics of Intermittent and Prolonged Infusions of Piperacillin/Tazobactam Using Monte Carlo Simulations and Steady-State Pharmacokinetic Data From Hospitalized Patients,&quot; <i>Ann Pharmacother</i>, 2009, 43(11):1747-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/19809009/pubmed\" target=\"_blank\" id=\"19809009\">19809009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &quot;Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/PMID:20034345[PubMed - indexed for MEDLINE] Free full text /pubmed\" target=\"_blank\" id=\"PMID:20034345[PubMed - indexed for MEDLINE] Free full text \">PMID:20034345[PubMed - indexed for MEDLINE] Free full text </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/PMID:20034345[PubMed - indexed for MEDLINE] Free full text /pubmed\" target=\"_blank\" id=\"PMID:20034345[PubMed - indexed for MEDLINE] Free full text \">PMID:20034345[PubMed - indexed for MEDLINE] Free full text </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Waters CD, Young DC, et al, &quot;Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins,&quot; <i>Pediatr Pulmonol</i>, 2013, 48(2):107-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-and-tazobactam-sodium-pediatric-drug-information/abstract-text/22949297/pubmed\" target=\"_blank\" id=\"22949297\">22949297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zosyn (piperacillin/tazobactam) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; December 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12708 Version 145.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F210401\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F210402\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049416\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675525\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049409\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F210378\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F210362\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049419\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F210395\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049418\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F210432\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F210428\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F210385\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F210366\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299884\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F210371\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F210387\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049415\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F210365\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F210384\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F6856652\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F210390\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12708|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">Piperacillin and tazobactam sodium: Drug information</a></li><li><a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-patient-drug-information\" class=\"drug drug_patient\">Piperacillin and tazobactam sodium: Patient drug information</a></li></ul></div></div>","javascript":null}